KRAS and infection: The DAAs ombitasvir ([OBV] a NS5A inhibitor) and paritaprevir ([PTV] an NS3/4A protease inhibitor identified by AbbVie and Enanta and codosed with the pharmacokinetic enhancer ritonavir [r]) are approved for the treatment of genotype 4 infection; OBV/PTV/r with the DAA dasabuvir ([DSV] a NS5B nonnucleoside polymerase inhibitor) with or without RBV is approved for treatment of genotype 1 infection [12, 13].